PSYCH Symposium is returning at the British Museum on 6 July, when a panel of experts will discuss how psychedelics

With a growing belief that research around the potential of psychedelics is finally making key policymakers within the European Parliament

PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and

When MAPS completed its Phase IIIa trials with MDMA in the treatment of PTSD, the subsequent data release grabbed headlines

A debate on ‘Psilocybin Access Rights’ is expected to be heard in the House of Commons later this month. The

On 19 April 1943, eighty years ago today, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the

 We have witnessed an exponential increase in the number of companies developing proprietary analogues  of psychedelic compounds such as psilocybin,

Contributed article by Matt Zorn, Partner at Yetter Coleman, for The Psychedelics As Medicine Report: Fourth Edition.  The patent portfolio

Regulatory reform to decriminalise the use of psilocybin is taking place in a dozen states across the US, and is

At the end of last year, Beckley Psytech announced the acquisition of life science company Eleusis. The procurement was largely

A clinical trial at the University of Wisconsin–Madison is studying psilocybin therapy in the treatment of methamphetamine and opioid use

MAPS recently announced positive results from its second Phase III trial with MDMA-assisted therapy in the treatment of PTSD, with